ALL-trans retinoic acid (ATRA) may improve results of chemotherapy in poor prognosis non-APL AML and MDS: A randomized study.

被引：0
|
作者：
Estey, E [1 ]
Beran, M [1 ]
Pierce, S [1 ]
Kantarjian, H [1 ]
Keating, M [1 ]
机构：
[1] UNIV TEXAS,MD ANDERSON CANCER CTR,HOUSTON,TX 77030
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1851 / 1851
页数：1
相关论文
共 50 条
  • [1] Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL))
    Kueley-Bagheri, Yasemin
    Kreuzer, Karl-Anton
    Monsef, Ina
    Luebbert, Michael
    Skoetz, Nicole
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (08):
  • [2] Myelodysplastic syndrome (MDS) transforming to acute promyelocytic leukemia (APL) with sustained response to all-trans retinoic acid (ATRA).
    Lima, CMR
    Stuart, RK
    BLOOD, 1996, 88 (10) : 3433 - 3433
  • [3] All-Trans-Retinoic Acid (ATRA) Causes Extensive Differentiation In the NPM Mutant, Non-APL Leukemic Cell Line OCI-AML3
    Kutny, Matthew A.
    Collins, Steven J.
    Loeb, Keith
    Walter, Roland B.
    Meshinchi, Soheil
    BLOOD, 2010, 116 (21) : 1354 - 1354
  • [4] All-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) to minimize or eliminate chemotherapy in untreated APL.
    Estey, EH
    Faderl, S
    Giles, F
    Thomas, D
    Ferrajoli, A
    Wierda, W
    Verstovsek, S
    Garcia-Manero, G
    Kantarjian, HM
    BLOOD, 2003, 102 (11) : 618A - 619A
  • [5] EFFECTIVE ARSENIC TRIOXIDE/ALL-TRANS RETINOIC ACID (ATRA) REGIMEN WITHOUT CHEMOTHERAPY FOR PEDIATRIC ACUTE PROMYELOCYTIC LEUKEMIA (APL)
    Zhu, K.
    Absalon, M.
    McMasters, R.
    Smolarek, T.
    Mo, J.
    Hess, L.
    Siekerman, M.
    Kumar, A.
    Siekerman, M.
    Phillips, C.
    O'Brien, M.
    Basu, M.
    Perentesis, J.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : 74 - 74
  • [6] A phase II study of all-trans retinoic acid (ATRA) with prednisolone prophylaxis in the treatment of acute promyelocytic leukemia (APL).
    Firkin, FC
    Matthews, JP
    Bradstock, KF
    Wiley, JS
    BLOOD, 1999, 94 (10) : 228B - 228B
  • [7] Treatment of relapsing acute promyelocytic leukemia (APL) with arsenic trioxide (As203) ± all-trans retinoic acid (ATRA):: The French As98 study.
    Dombret, H
    Rousselot, P
    Hermine, O
    Fermand, JP
    Poupon, J
    Daniel, MT
    Chomienne, C
    Tibbi, A
    Lebbé, G
    Solbes-Latourette, S
    Brouet, JC
    Varet, B
    Degos, L
    BLOOD, 2000, 96 (11) : 828A - 828A
  • [8] Randomized phase II trial of fludarabine plus Ara-C plus idarubicin ± all-trans retinoic acid (ATRA) ± G-CSF in poor-prognosis newly-diagnosed AML and MDS.
    Estey, E
    Thall, P
    Pierce, S
    Freireich, E
    BLOOD, 1998, 92 (10) : 233A - 233A
  • [9] CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia (APL) treated with simultaneous all-trans retinoic acid (ATRA) and chemotherapy.
    Ferrara, F
    Morabito, F
    Martino, B
    Specchia, G
    Liso, V
    Boccuni, P
    Di Noto, R
    Pane, F
    Annunziata, M
    Schiavone, EM
    Guglielmi, C
    Del Vecchio, L
    Lo Coco, F
    BLOOD, 1999, 94 (10) : 696A - 696A
  • [10] Outcome of childhood acute promyelocytic leukemia (APL) with all trans retinoic acid (ATRA) and chemotherapy (CT): Results in 31 cases.
    de Botton, S
    Coiteux, V
    Chevret, S
    Rayon, C
    Vilmer, E
    Sanz, M
    de la Serna, J
    Philippe, N
    Baruchel, A
    Blanche, S
    Leverger, G
    Robert, A
    Audhuy, B
    Brault, P
    Simon, M
    Sotto, JJ
    Bernard, F
    Bordessoule, D
    Fegueux, N
    Bouscary, D
    San Miguel, J
    Conde, E
    Vekhoff, A
    Parry, A
    Chomienne, C
    Degos, L
    Fenaux, P
    BLOOD, 2002, 100 (11) : 35A - 35A
12345